As the world continues to grapple with the long-term consequences of the SARS-CoV-2 pandemic, emerging evidence is sharpening focus on one of its most concerning legacies: the heightened risk of cardiovascular disease among individuals experiencing long COVID. What began as anecdotal reports of persistent fatigue and breathlessness has evolved into a robust body of research indicating that the virus can depart a lasting imprint on the heart and circulatory system, even in those who initially had mild infections.
Recent studies from Scandinavia and France have provided some of the most compelling data to date, revealing that long COVID is not merely a syndrome of lingering symptoms but a condition with measurable implications for heart health. These findings are prompting renewed calls for vigilant post-infection monitoring, particularly among those who required hospitalization during their acute illness.
A study conducted in Sweden and published in early 2026 found that individuals with long COVID face a significantly elevated risk of developing cardiovascular complications, including arrhythmias, heart failure and thromboembolic events. The research, led by scientists at the Karolinska Institutet and Lund University, tracked hundreds of patients over an extended period and observed that the increased risk persisted regardless of the initial severity of infection — though it was most pronounced in those who had been hospitalized.
“We saw a clear signal that long COVID is associated with a higher likelihood of cardiovascular disease,” said Dr. Artur Fedorowski, professor of cardiology at Lund University and one of the study’s lead authors. “This wasn’t limited to older patients or those with pre-existing conditions. Even younger, previously healthy individuals showed signs of cardiac strain months after their initial infection.”
The Swedish findings align with broader European research. A report from the European Society of Cardiology (ESC), released in late 2025, emphasized that cardiac involvement in long COVID can manifest in multiple ways — from inflammation of the heart muscle (myocarditis) to disturbances in heart rhythm and increased clotting risk. The ESC noted that these complications can emerge weeks or months after the acute phase and may persist for up to three years in some cases.
“The cardiovascular impact of long COVID is becoming impossible to ignore,” stated Peggy Robert, a health journalist with France Info who co-reported on the ESC’s findings. “What we’re seeing is a pattern where the virus doesn’t just leave the body after recovery — in some people, it triggers a cascade of effects that affect the heart and blood vessels long after the infection has cleared.”
One of the most striking aspects of the data is the proportion of long COVID patients affected. According to the ESC report, approximately 5% of all individuals infected with SARS-CoV-2 may develop a form of long COVID with prominent cardiovascular symptoms. Globally, this translates to an estimated 5 million people facing potential heart-related complications stemming from their infection.
Symptoms such as chest pain, palpitations, unexplained shortness of breath, and disproportionate fatigue during exertion are increasingly recognized as red flags that warrant cardiac evaluation. Medical experts stress that these signs should not be dismissed as mere anxiety or deconditioning, particularly when they persist beyond the expected recovery window.
“Patients often describe feeling like their heart is ‘racing’ or ‘skipping beats’ without any clear trigger,” explained Dr. Pia Lindberg, a doctoral researcher at Karolinska Institutet involved in the Swedish study. “When we investigate further, we frequently find objective evidence of arrhythmia or reduced cardiac function — even when standard tests initially appeared normal.”
The mechanisms behind this cardiac involvement remain under investigation, but researchers point to several possible pathways. These include persistent viral reservoirs in tissue, autoimmune-like responses where the body attacks its own heart tissue, endothelial dysfunction affecting blood vessel lining, and microclot formation that impairs circulation. Each of these theories is being explored in ongoing studies across Europe and North America.
In response to these risks, health authorities in several countries are beginning to refine guidance for long COVID care. The UK’s National Institute for Health and Care Excellence (NICE) updated its recommendations in early 2026 to include proactive cardiovascular screening for long COVID patients with suggestive symptoms. Similarly, the German Society of Cardiology has urged general practitioners to consider echocardiograms and Holter monitoring as part of routine follow-up for post-COVID patients reporting cardiac-type complaints.
Vaccination continues to play a protective role, though its exact impact on reducing long-term cardiac risk is still being studied. Preliminary data suggest that individuals who were vaccinated prior to infection may have a lower likelihood of developing severe long COVID manifestations, including those affecting the heart. Yet, breakthrough infections can still lead to long-term complications, underscoring the need for continued vigilance.
For patients navigating life after COVID, the message from clinicians is clear: listen to your body. Persistent symptoms should prompt a conversation with a healthcare provider, and when cardiac concerns are involved, timely evaluation can make a difference. “We’re not trying to alarm people,” said Dr. Fedorowski. “We’re trying to ensure that those who need help get it — before a treatable issue becomes something more serious.”
As research progresses, the focus is shifting toward identifying biomarkers that could predict who is most at risk for cardiovascular long COVID, as well as testing potential interventions. Trials are underway examining the use of anticoagulants, anti-inflammatory agents, and cardiac rehabilitation programs tailored to post-COVID patients.
The next major update on this topic is expected from the European Society of Cardiology, which has announced plans to present updated guidance on managing cardiovascular complications in long COVID at its annual congress in August 2026. Until then, the medical community continues to emphasize the importance of integrated, patient-centered care that addresses both the visible and hidden consequences of the pandemic.
If you or someone you recognize is experiencing ongoing symptoms after a COVID-19 infection — especially chest discomfort, irregular heartbeat, or unexplained fatigue — consider speaking with a doctor about cardiac evaluation. Sharing experiences and staying informed helps not only individual recovery but also the broader understanding of how this virus affects long-term health.